Journal Article
Review
Add like
Add dislike
Add to saved papers

[Chronic kidney disease (CKD) and bone. Regulation of calcium and phosphate metabolism by FGF23/Klotho].

Clinical Calcium 2009 April
Fibroblast growth factor 23 (FGF23) is a hormone which is produced by osteocytes and lowers serum phosphate and 1,25-dihydroxyvitamin D levels by binding to Klotho-FGF receptor complex in kidney. It has been shown that excess actions of FGF23 cause hypophosphatemic diseases white deficient actions of FGF23 result in hyperphosphatemic disorders. It should be tested in the future whether development of methods to modify FGF23 actions leads to novel therapeutic approaches for bone and mineral disorders.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app